Peer-Reviewed Publication
Leukemia2026July 17, 2026Journal Article
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Max S Topp1, Bijal D Shah2, Elias Jabbour3, Jae H Park4, Paul Shaughnessy5, Aaron C Logan6, Karamjeet S Sandhu7, Mehrdad Abedi8, Michael R Bishop9, Daniel J DeAngelo10, Xiang Yin11, Ruthanna Davi11, Katharine Hodby12, Ram Malladi13, Wolfram Brugger14, Justin Shang15, Claire Roddie16, Hagop M Kantarjian3
1University Hospital of Würzburg, Würzburg, Germany. Topp_M@ukw.de.
2Moffitt Cancer Center, Tampa, FL, USA.
3University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5Methodist Hospital, San Antonio, TX, USA.
6University of California at San Francisco, San Francisco, CA, USA.
7City of Hope National Medical Center, Duarte, CA, USA.
8University of California Davis, Davis, CA, USA.
9University of Chicago, Chicago, IL, USA.
10Dana-Farber Cancer Institute, Boston, MA, USA.
11Medidata, New York, NY, USA.
12University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
13Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
14Autolus Therapeutics, Munich, Germany.
15Autolus Therapeutics, Rockville, MD, USA.
16University College London Cancer Institute, London, UK.
Abstract
In the single-arm Phase Ib/II FELIX study (NCT04404660), obecabtagene autoleucel (obe-cel; CD19-directed autologous CAR T-cell therapy) demonstrated high overall remission rates (ORR) and a favorable safety profile in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To contextualize results from FELIX, we compared the efficacy and safety of obe-cel with matched ex…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans